HC Wainwright Has Bullish Outlook for RIGL FY2025 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – HC Wainwright boosted their FY2025 earnings per share estimates for Rigel Pharmaceuticals in a research report issued on Tuesday, January 13th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of $6.68 for the year, up from their prior estimate of $6.49. HC Wainwright has a “Buy” rating and a $57.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q4 2025 earnings at $1.34 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.93 by $0.53. The company had revenue of $69.46 million for the quarter, compared to analysts’ expectations of $61.88 million. Rigel Pharmaceuticals had a return on equity of 204.70% and a net margin of 40.17%.

RIGL has been the subject of several other reports. Citigroup reissued a “buy” rating on shares of Rigel Pharmaceuticals in a research note on Wednesday. Zacks Research upgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. Wall Street Zen upgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, December 21st. Cantor Fitzgerald increased their price objective on shares of Rigel Pharmaceuticals from $32.00 to $38.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Rigel Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $43.20.

Rigel Pharmaceuticals Stock Down 5.0%

Rigel Pharmaceuticals stock opened at $37.96 on Wednesday. The firm has a market capitalization of $688.97 million, a price-to-earnings ratio of 6.15 and a beta of 1.11. The firm’s fifty day moving average price is $43.20 and its two-hundred day moving average price is $34.36. Rigel Pharmaceuticals has a 1-year low of $15.50 and a 1-year high of $52.24. The company has a current ratio of 2.28, a quick ratio of 2.14 and a debt-to-equity ratio of 0.25.

Institutional Trading of Rigel Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. AlphaQuest LLC increased its stake in shares of Rigel Pharmaceuticals by 234.8% in the third quarter. AlphaQuest LLC now owns 1,105 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 775 shares in the last quarter. IFP Advisors Inc purchased a new stake in shares of Rigel Pharmaceuticals during the 3rd quarter valued at approximately $55,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Rigel Pharmaceuticals during the 3rd quarter valued at approximately $62,000. RMG Wealth Management LLC bought a new position in Rigel Pharmaceuticals in the 2nd quarter worth approximately $41,000. Finally, Wexford Capital LP purchased a new position in Rigel Pharmaceuticals in the 3rd quarter valued at approximately $66,000. 66.23% of the stock is currently owned by institutional investors.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).